title: Clinical outcomes of single dose stereotactic radiotherapy for lung metastases.
abstract: BACKGROUND
  Stereotactic body radiation therapy is an emerging noninvasive technique for the treatment of oligometastatic cancer. The use of small numbers of large doses achieve a high percentage of local control. The aim of this study was to evaluate the efficacy and tolerability of SBRT for the treatment of lung metastases in a cohort of patients treated between 2008 and 2012 at our institution.
  
  
  METHODS
  A total of 66 patients with oligometastatic lung tumors (single pulmonary nodules in 40 patients; 61%) were included in the study. SBRT was performed with a stereotactic body frame and a 3-D conformal technique. Forty-nine central tumors received 23 Gy in a single fraction and 54 peripheral tumors received a dose of 30 Gy in a single fraction. The primary end point was local control; secondary end points were survival and toxicity.
  
  
  RESULTS
  Median follow-up was 15 months (range, 3-45 months). Local control rates at 1 and 2 years were 89.1% and 82.1%, overall survival rates were 76.4% and 31.2%, cancer-specific survival rates were 78.5% and 35.4%, and progression-free survival rates were 53.9% and 22%, respectively. Median survival time was 12 months, and median progression-free survival time was 10 months. Toxicity profiles were good, with 2 cases of Grade 3 toxicity (pneumonitis).
  
  
  CONCLUSIONS
  SBRT is an effective and safe local treatment option for patients with lung metastases, although it remains investigational; longer follow-up to confirm results is required.
authors.affiliation: Department of Radiation Oncology, Sant'Andrea Hospital, "Sapienza" University of Rome, Italy.
authors.forename: Mattia F
authors.initials: MF
authors.lastname: Osti
authors.forename: Alessia
authors.initials: A
authors.lastname: Carnevale
authors.forename: Maurizio
authors.initials: M
authors.lastname: Valeriani
authors.forename: Vitaliana
authors.initials: V
authors.lastname: De Sanctis
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Minniti
authors.forename: Enrico
authors.initials: E
authors.lastname: Cortesi
authors.forename: Massimo
authors.initials: M
authors.lastname: Martelli
authors.forename: Riccardo
authors.initials: R
authors.lastname: Maurizi Enrici
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D024221:Antineoplastic Protocols; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D002277:Carcinoma / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary; D003110:Colonic Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011014:Pneumonia / Q000209:etiology; D016634:Radiosurgery / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome
keywords: Linear accelerator; Local control; Oligometastases; Pneumonitis